Conclusion of a non-exclusive rebate agreement according to § 130a para. 8 SGB V for the active ingredient Budesonide (FAM Kinpeygo and interchangeable medicines), ATC A07EA06 for the period 01.08.2026 - 31.07.2028
About This Opportunity
This is a supplies contract in the health and medical services and general supplies sectors, with a focus on Pharmaceuticals. Located in Germany, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 1.
Published through DÖE Bekanntmachungsservice (Germany), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. Interested parties should review the full documentation on the original source before submitting their proposal.
Description
Auto-translated from German§ 130a Paragraph 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework rebate agreements for medicines to be dispensed at the expense of statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, DAK-Gesundheit regularly conducts formal award procedures based on active ingredients according to the regulations of the 4th part of the GWB. For medicines for the above-mentioned active ingredient Budesonide (FAM Kinpeygo and interchangeable medicines), ATC A07EA06, to be specified by the bidder in Appendix 2 to the contract, DAK-Gesundheit intends to conclude medicine rebate agreements with as many interested pharmaceutical companies as possible until new medicine rebate agreements come into force. A rebate agreement within the framework of the licensing model for the above-mentioned active ingredient will first come into force on 01.08.2026 and will end on 31.07.2028. It will automatically end regardless of this upon the entry into force of the exclusive contract.
Data provenance
This notice is sourced from DÖE Bekanntmachungsservice (Germany) and was originally published on June 11, 2026. Last refreshed 1 day ago. Original language: German. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About DAK-Gesundheit
DAK-Gesundheit has issued 166 procurement notices on BidsFactory, including 95 currently open and 44 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Information & Communication Technology. All notices are published for Germany. Notices are distributed via TED - Tenders Electronic Daily (EU), service.bund.de (Germany), and DÖE Bekanntmachungsservice (Germany). Most recent publication: June 18, 2026.
Frequently asked questions about this tender
Where will the contract be performed?
The contract is for delivery in Germany. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
How can I submit a bid?
Visit DÖE Bekanntmachungsservice (Germany) to access the full notice, required documents, and submission instructions provided by the contracting authority.
Who is the contracting authority?
This notice was issued by DAK-Gesundheit in Germany. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
What is the estimated budget?
The estimated contract value is Up to €1. Bidders should ensure their proposals are consistent with this range and account for any local taxes and contract execution costs.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.